Vaccines Manufacturing and Innovation Centre Fast Tracked as Works Progress at Harwell Campus
Construction of the UK’s New Vaccines Centre by Glencar Construction Starts Well Ahead of Schedule as Timelines are Fast Tracked Due to Covid-19
Harwell, Oxfordshire: Work has begun ahead of schedule to build the highly specialist facility that will house the Vaccines Manufacturing and Innovation Centre (VMIC). VMIC, a not for profit organisation, will provide the country’s first bespoke strategic vaccine development and manufacturing capability.
A rapidly accelerated programme will aim to see the 7,000 m2 (75,000 sq ft - footprint) state-of-the-art facility opening its doors in 2021, ahead of the original scheduled date in 2022.
VMIC was established by University of Oxford, Imperial College and London School of Hygiene and Tropical Medicine with support from industrial partners, Merck Sharp and Dohme, Johnson and Johnson, and GE Healthcare. The Centre’s main funding comes through a £65 million grant from UK Research and Innovation, as part of the UK Government’s Industrial Strategy Challenge Fund.
Dr Matthew Duchars, Chief Executive of the Vaccines Manufacturing and Innovation Centre said: “Whilst no-one could have predicted the Covid-19 outbreak we are doing all we can to fast track the build so VMIC is set-up to offer long-term support to the UK’s future vaccines needs whilst simultaneously contributing right now to the vital work that will help us emerge from this pandemic.
“As well as working with the Harwell team and contractors to deliver the build rapidly ahead of schedule, VMIC scientists and engineers are working round the clock as part of the BIA CoViD19 Taskforce, and alongside Oxford University advising on manufacturing options of the vaccine candidate ChAdOx1 nCoV-19, which has recently opened for trial.”
- Related Links